exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the
Company profile
Ticker
LFWD
Exchange
Website
CEO
Lawrence Jasinski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
Argo Medical Technologies Ltd.
SEC CIK
Corporate docs
Subsidiaries
Lifeward, Inc. • Lifeward CA, Inc. • Lifeward GmbH ...
LFWD stock data
Latest filings (excl ownership)
8-K
Lifeward Announces the Appointment of Mike Swinford to its
19 Apr 24
8-K
Other Events
4 Apr 24
8-K
Investor Presentation April 2024
3 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Lifeward Reports Fourth Quarter and Full Year 2023
27 Feb 24
8-K
Other Events
30 Jan 24
8-K
Other Events
19 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
ReWalk Robotics Reports Third Quarter 2023 Financial Results
14 Nov 23
8-K/A
Financial Statements and Exhibits
27 Oct 23
Transcripts
LFWD
Earnings call transcript
2023 Q4
27 Feb 24
LFWD
Earnings call transcript
2023 Q3
14 Nov 23
LFWD
Earnings call transcript
2023 Q2
11 Aug 23
LFWD
Earnings call transcript
2023 Q2
11 Aug 23
LFWD
Earnings call transcript
2023 Q1
11 May 23
LFWD
Earnings call transcript
2022 Q4
23 Feb 23
LFWD
Earnings call transcript
2022 Q3
7 Nov 22
LFWD
Earnings call transcript
2022 Q2
9 Aug 22
LFWD
Earnings call transcript
2022 Q1
17 May 22
LFWD
Earnings call transcript
2021 Q4
26 Feb 22
Latest ownership filings
4
Michael Swinford
22 Apr 24
3
Michael Swinford
22 Apr 24
4
Change in insider ownership
21 Nov 23
144
Notice of proposed sale of securities
20 Nov 23
144
Notice of proposed sale of securities
17 Nov 23
4
Change in insider ownership
16 Nov 23
4
Change in insider ownership
28 Sep 23
SC 13D/A
Lind Global Fund II LP
28 Sep 23
4
Randel Richner
19 Sep 23
4
Lawrence J Jasinski
19 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.29 mm | 33.29 mm | 33.29 mm | 33.29 mm | 33.29 mm | 33.29 mm |
Cash burn (monthly) | 8.52 mm | 3.45 mm | 2.65 mm | 1.87 mm | 2.48 mm | 1.67 mm |
Cash used (since last report) | 58.63 mm | 23.75 mm | 18.23 mm | 12.90 mm | 17.08 mm | 11.53 mm |
Cash remaining | -25.35 mm | 9.54 mm | 15.06 mm | 20.39 mm | 16.20 mm | 21.76 mm |
Runway (months of cash) | -3.0 | 2.8 | 5.7 | 10.9 | 6.5 | 13.0 |
Institutional ownership, Q3 2023
25.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 8 |
Closed positions | 10 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.60 bn |
Total shares | 15.35 mm |
Total puts | 0.00 |
Total calls | 2.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lind Global Fund II | 9.89 mm | $7.20 mm |
Intracoastal Capital | 2.39 mm | $2.93 mm |
Advisor | 1.91 mm | $1.45 bn |
CVI Investments | 648.10 k | $0.00 |
Renaissance Technologies | 252.00 k | $192.00 k |
Mercer Global Advisors | 44.40 k | $34.00 k |
Snowden Capital Advisors | 30.00 k | $22.80 mm |
VIRT Virtu Financial | 29.75 k | $23.00 k |
Geode Capital Management | 29.64 k | $22.53 mm |
HighTower Advisors | 20.45 k | $15.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Michael Swinford | Ordinary Shares, par value NIS 1.75 per share | Grant | Acquire A | No | No | 0 | 10,040 | 0.00 | 10,040 |
20 Nov 23 | Lind Global Fund II | Ordinary Shares, par value NIS 0.25 per share | Buy | Acquire P | No | No | 0.73 | 12,000 | 8.76 k | 10,017,745 |
17 Nov 23 | Lind Global Fund II | Ordinary Shares, par value NIS 0.25 per share | Buy | Acquire P | No | No | 0.73 | 42,917 | 31.33 k | 10,005,745 |
14 Nov 23 | Lind Global Fund II | Ordinary Shares, par value NIS 0.25 per share | Buy | Acquire P | No | No | 0.68 | 72,818 | 49.52 k | 9,962,828 |
26 Sep 23 | Lind Global Fund II | Ordinary Shares, par value NIS 0.25 per share | Sell | Dispose S | Yes | No | 0.7 | 5,031,200 | 3.52 mm | 0 |
26 Sep 23 | Lind Global Fund II | Ordinary Shares, par value NIS 0.25 per share | Buy | Acquire P | Yes | No | 0.7 | 5,031,200 | 3.52 mm | 9,890,010 |
News
HC Wainwright & Co. Reiterates Buy on Rewalk Robotics, Maintains $9 Price Target
15 Apr 24
Lifeward CEO Issues Open Letter To Shareholders On Progress To Finalize Exoskeleton Medicare Payment Rate
1 Apr 24
Lifeward Announces That Effective With The Open Of The Market On Friday, March 15, 2024, The Co Will Complete A 1-For-7 Reverse Split Of Its Ordinary Shares To Regain Compliance With Nasdaq Listing Requirements
13 Mar 24
ReWalk Robotics Ltd. (DBA Lifeward) Announces The Centers For Medicare & Medicaid Services Is Deferring Its Final Decision On The Payment Rate For Personal Exoskeletons
1 Mar 24
HC Wainwright & Co. Reiterates Buy on Rewalk Robotics, Maintains $3 Price Target
28 Feb 24
Press releases
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
19 Apr 24
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
12 Apr 24
Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
1 Apr 24
VA STAND Act introduced in the United States Senate
22 Mar 24
Lifeward Announces Reverse Share Split
13 Mar 24